NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders.
There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed an integrated drug discovery pipeline to identify and discover drugs for disease-causing ncRNAs.
For many ncRNAs, their function depends on direct interactions with proteins. NextRNA has developed and optimized a high-throughput screening platform to discover RNA-protein interactions and screen for molecules that disrupt these disease-relevant interactions. This platform is a key element in an integrated drug discovery pipeline that combines informatic tools, traditional methods, and novel approaches to develop RNA-directed therapies.
Originally developed in the Novina Lab at the Dana-Farber Cancer Institute, the company says its approach has the potential to address a broad range of diseases including cancer, infectious diseases, and autoimmune disorders.
Subscribe for alerts on new companies featured on Startups.Bio
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
